Search Results - "Jolma, T"

Economic burden and quality of life impairment increase with severity of PD by Keränen, T, Kaakkola, S, Sotaniemi, K, Laulumaa, V, Haapaniemi, T, Jolma, T, Kola, H, Ylikoski, A, Satomaa, O, Kovanen, J, Taimela, E, Haapaniemi, H, Turunen, H, Takala, A

“…Purpose. To define the interrelationship between cost-of-illness, quality of life (QoL) and Parkinson's disease (PD) severity in a common patient management…”
Get full text

Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study) by Myllylä, V., Haapaniemi, T., Kaakkola, S., Kinnunen, E., Hartikainen, P., Nuutinen, J., Rissanen, A., Kuopio, A. M., Jolma, T., Satomaa, O., Heikkinen, H.

“…Objectives and methods –  This study investigated the ease with which 52 Parkinson's disease patients already receiving adjunct entacapone to traditional…”
Get full text

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study by OʼConnor, Paul, Comi, Giancarlo, Freedman, Mark S, Miller, Aaron E, Kappos, Ludwig, Bouchard, Jean-Pierre, Lebrun-Frenay, Christine, Mares, Jan, Benamor, Myriam, Thangavelu, Karthinathan, Liang, Jinjun, Truffinet, Philippe, Lawson, Victoria J, Wolinsky, Jerry S

“…OBJECTIVE:To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) of the pivotal phase 3…”
Get full text

Phenotype of a homozygous CADASIL patient in comparison to 9 age-matched heterozygous patients with the same R133C Notch3 mutation by TUOMINEN, Susanna, JUVONEN, Vesa, VIITANEN, Matti, KALIMO, Hannu, AMBERLA, Kaarina, JOLMA, Tapani, RINNE, Juha O, TUISKU, Seppo, KURKI, Timo, MARTTILA, Reijo, PÖYHÖNEN, Minna, SAVONTAUS, Marja-Liisa

“…CADASIL is an autosomal dominant arteriopathy, characterized by multiple brain infarcts, cognitive decline, and finally dementia, which is caused by mutations…”
Get full text

Twelve-month safety of entacapone in patients with Parkinson's disease by Myllylä, V. V., Kultalahti, E.-R., Haapaniemi, H., Leinonen, M.

“…The safety of entacapone combined with levodopa and a dopadecarboxylase (DDC) inhibitor was tested in a 12‐month double‐blind study of 326 patients with…”
Get full text

Effects of L-tryptophan treatment on central indoleamine metabolism and short-lasting neurologic disturbances in multiple sclerosis by Hyyppä, M T, Jolma, T, Riekkinen, P, Rinne, U K

“…Twelve MS patients were treated with L-tryptophan with or without decarboxylase inhibitor for 30 days, and the daily dose was either 1.5 g or 8 g. Tryptophan,…”
Get full text

Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study

“…BACKGROUND AND PURPOSE: To test the design and feasibility of a very large randomised controlled trial assessing the efficacy and safety of antithrombotic…”
Get full text

L-tryptophan treatment and the episodic secretion of pituitary hormones and cortisol by Hyyppä, M T, Jolma, T, Liira, J, Långvik, V A, Kytömäki, O

Get more information

L-tryptophan and neuroendocrine regulation in neurologic patients: hormone responses to L-tryptophan loading in patients with hypothalamic lesions by Hyyppä, M T, Jolma, T, Långvik, V A, Kytömäki, O, Syvälahti, E

Get more information

X-linked adrenoleukodystrophy--an explanation for school problems of boys,walking problems of men and Addison disease by Vainionpää, L, Salo, M K, Jolma, T, Laitinen, J, Nikkari, T, Leisti, J

Get full text